Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod.

Virginia Palomares CabezaLaura Y L KummerLuuk WieskeRuth R HagenMariel DuurlandVeronique A L KonijnKoos P J van DamEileen W StalmanCarolien E van de SandtLaura BoekelNiels J M VerstegenMaurice SteenhuisTheo RispensSander W TasGerrit J WolbinkJoep KillesteinTaco W KuijpersS Marieke van HamFilip EftimovAnja Ten BrinkeZoé L E van Kempennull null

Published in: Neurology(R) neuroimmunology & neuroinflammation (2022)

In ocrelizumab-treated patients with MS, a third SARS-CoV-2 vaccination had no additive effect on the maximal T-cell response but did induce a boost response. In fingolimod-treated patients, no T-cell responses could be detected following both a second and third SARS-CoV-2 vaccination.

Keyphrases

sars cov
multiple sclerosis
respiratory syndrome coronavirus
newly diagnosed
end stage renal disease
ejection fraction
chronic kidney disease
mass spectrometry
prognostic factors
ms ms
heart rate
patient reported outcomes